SYS-6002 (CRB-701) Phase 1 Data to be Presented at 2024 ASCO

NORWOOD, Mass., May 23, 2024 – Corbus Pharmaceuticals (NASDAQ: CRBP), a precision oncology company, announced the release of an abstract for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, scheduled from May 31 to June 4 in Chicago. The abstract, titled "Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate," will be showcased on June 1. Dr. Jian Zhang from Fudan University Shanghai Cancer Center will present the poster, which updates previous data with three additional months of clinical information.

The trial focuses on evaluating the safety and tolerability of SYS6002 (CRB-701), a next-generation antibody drug conjugate targeting Nectin-4. This study aims to determine the Maximum Tolerated Dose (MTD) and the appropriate Phase 2 dose for patients with advanced solid tumors who have not responded to standard treatments. The dose escalation study spans seven levels, from 0.2 mg/kg to 4.5 mg/kg, employing a Bayesian Optimal Interval (BOIN) design with accelerated titration. Initial pharmacokinetic (PK) cohorts have begun at the 2.7 mg/kg and 3.6 mg/kg dose levels.

Participants in the trial were selected based on Nectin-4 staining, except for metastatic urothelial cancer patients, who were presumed Nectin-4 positive. Besides safety and tolerability, the study also reports on the pharmacokinetics and preliminary anti-tumor activity of SYS6002 (CRB-701). The research is conducted in collaboration with CSPC in China, and Corbus has initiated a Phase 1 dose-escalation study in the United States, dosing the first patient in April 2024.

About CRB-701

CRB-701, also known as SYS6002, is an advanced antibody drug conjugate targeting Nectin-4. It features a site-specific cleavable linker and a homogenous drug-to-antibody ratio of 2, utilizing MMAE as the payload. Nectin-4 is a validated tumor-associated antigen in urothelial cancer. The drug is administered on a Q3W schedule, which aims to reduce free-MMAE concentrations in plasma and associated toxicities, thereby potentially increasing patient compliance and convenience compared to other treatments like PADCEV® (enfortumab vedotin).

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., headquartered in Norwood, Massachusetts, is dedicated to pioneering precision oncology treatments. The company’s portfolio includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4, CRB-601, an anti-integrin monoclonal antibody that inhibits TGFβ activation, and CRB-913, a CB1 inverse agonist designed for obesity treatment.

Corbus Pharmaceuticals strives to defeat serious illnesses by leveraging innovative scientific approaches to well-understood biological pathways. The company is actively involved in developing treatments that offer hope to patients who have limited options due to the aggressive nature of their diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!